A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

NCT03126097 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopping rules were met.

Conditions

Healthy

Interventions

DRUG: JNJ-64155806 150 mg
DRUG: Ethinylestradiol/drospirenone 0.02 mg/3 mg
DRUG: COCP Placebo

Sponsor

Janssen Research & Development, LLC